Carmat SA Sustainability Reports

Carmat S.A. designs, develops, and markets a total artificial heart (Aeson®) aimed at treating patients with end-stage biventricular heart failure.

Sector: Manufacturing

Country: France

Exchange: Euronext Paris

LEI: 969500ARXACM0P0KH333

FIGI: BBG001T902M7

9 reports from 2011 to 2022

• Carmat SA 2022 Universal Registration Document
• Carmat SA 2021 Universal Registration Document
• Carmat SA 2020 Universal Registration Document
• Carmat SA 2019 Universal Registration Document Including Annual Financial Report
• Carmat SA 2018 Registration Document Including Annual Financial Report